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Abstract
The aimof the studywas to compare self-reported and analytically conﬁrmed substance use in cases of acute recreational drug toxicity.
We performed a retrospective analysis of emergency department presentations of acute recreational drug toxicity over 2 years
(October 2013 to September 2015) within the European Drug Emergencies Network Plus project.
Among the 10,956 cases of acute recreational drug toxicity during the study period, 831 could be included. Between the self-
reported substance use and the toxicological results, the highest agreement was found for heroin (86.1%) and cocaine (74.1%),
whereas inhalants, poppers, and magic mushrooms were self-reported but not analytically detected. Cathinones and other new
psychoactive substances (NPS) could be detected using additional analytical methods. Among cases with both immunoassay (IA)
and conﬁrmation with mass spectrometry (MS), the results were consistent for methadone (100%) and cocaine (95.5%) and less
consistent for amphetamines (81.8%). In cases with a positive IA for amphetamines (n=54), MS conﬁrmed the presence of 3,4-
methylenedioxymethamphetamine (MDMA), amphetamine, methamphetamine, and NPS in 37, 20, 10, and 6 cases, respectively,
also revealing use of more than 1 substance in some cases. MS yielded positive results in 21 cases with a negative IA for
amphetamines, including amphetamine, MDMA, methamphetamine, and NPS, in 14, 7, 2, and 2 cases, respectively.
In conclusion, the highest agreement was found between self-reports and analytical ﬁndings for heroin and cocaine. The diagnosis
of NPS use was mainly based on self-report. The IAs accurately identiﬁed methadone and cocaine, and MS had advantages for the
detection of NPS and amphetamine derivatives.Editor: Tomasz Czarnik.
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The recreational use of psychoactive substances is common. In
the European Union, nearly 25% of the adult population has
tried illicit drugs in their lives.[1] In addition to classic, established,
recreational (illicit) drugs, many new psychoactive substances
(NPS) have emerged worldwide in the last decade.[2]
In most cases of acute recreational drug toxicity presenting to
the emergency department (ED), management is based on self-
reported substance use and clinical presentation. However,
relatively rapid analytical tests using immunoassays (IAs) can
provide preliminary information about the substances that are
used, especially if no other information is available by patient
self-report. IAs use speciﬁc antibodies to qualitatively determine
the presence of distinct drugs/drug classes.[3] Although relatively
fast and easy to use, IAs have limitations because they can yield
false-positives (e.g., cross reactivity with other compounds) or
false-negatives (e.g., poor speciﬁcity or concentrations below the
cut-off) and typically cannot detect NPS. Furthermore, the results
are only qualitative (i.e., positive/negative) and a suspected
positive result does not necessarily indicate acute intoxication.
IAs are generally unspeciﬁc and more costly and time-consuming
chromatographic methods (e.g., liquid chromatography [LC], gas
chromatography [GC]) combined with mass spectrometry (MS)
are needed for conﬁrmation in case of a positive IA.[3] LC that
uses very small particles in the stationary phase and a relatively
high pressure in the mobile phase is referred to as high-
performance LC. Tandem mass spectrometry (MS/MS) involves
multiple steps of MS selection.[4] Such methods are often more
sensitive and mostly more speciﬁc than IAs, but their costs, run
time (e.g., the results might not be available the same day), and
need for specialized personnel limit their use and beneﬁts in the
ED setting.
The present study compared self-reported and analytically
detected substances in cases of acute recreational drug toxicity
presenting to the ED. Our ﬁrst objective was to investigate
whether the analytical results that were obtained by IA and/or
additional analytical methods provided additional information to
the reports by the patients and proxies.We also investigated what
substances were detected in patients with use of unknown agent
(s) because knowing the substances used can inﬂuence the
patients’ management. Our second objective was to compare the
IA results with the results from additional chromatographic-MS
methods in cases in which both test results were available to
identify possible advantages of using additional methods in cases
of acute drug toxicity.
2. Materials and methods
The study was performed within the European Drug Emergencies
Network (Euro-DEN) Plus project, the ﬁrst year of which has
been previously described in detail.[5,6] Brieﬂy, using a minimum
dataset of key demographic, predeﬁned clinical, and outcome
variables, the Euro-DEN Plus project collected information on2ED presentations that had clinical features consistent with acute
recreational drug/NPS toxicity from 16 sentinel centers in 10
European countries. Presentations associated with prescription
or over-the-counter drugs were included if these drugs were used
for recreational purposes but not if the presentation was related
to self-harm or an adverse effect of a prescribed drug.
Presentations related to lone alcohol toxicity, or not directly
related to acute recreational drug toxicity (e.g., trauma and
withdrawal), or associated with self-harm were excluded. The
study was approved by the ethics committee of each participating
center and performed in accordance with the Declaration of
Helsinki.
Toxicological screening is not routinely being performed in all
Euro-DEN Plus centers and is therefore available only in the
minority of the cases; however, where it is undertaken as part of
routine clinical care the results are recorded in the Euro-DENPlus
database. The present study included only cases with analytical
conﬁrmation. The retrospective analysis was performed using
data collected during the ﬁrst 2 years of the Euro-DEN Plus
project (October 2013 to September 2015).
Data from the following centers were included: Basel,
Drogheda, Dublin, London (2 centers), Mallorca, Oslo, and
Paris. The following analytical tests were used: in Basel the
Cloned Enzyme Donor-IAs (CEDIA, Thermo Fisher Scientiﬁc,
Passau, Germany[7]), DRI IAs (Thermo Fisher Scientiﬁc[7]),
an enzymatic assay (Bühlmann, Allschwil, Switzerland), and
LC–MS/MS that covered over 770 substances, not including
synthetic cannabinoid receptor agonists (SCRAs)[8] in some of the
cases; in Drogheda, the CEDIA IA and enzyme multiplied IA
technique; in Dublin, the Alere Drug Screen Urine Test Panel[9]; in
London, the CEDIA IA (Thermo Fisher Scientiﬁc) and additional
LC–MS/MS in some cases; in Mallorca, the DRI IA (Thermo
Fisher Scientiﬁc) and GC–MS in some cases; in Oslo, ultra-high-
performance LC–MS/MS; in Paris, IAs were performed using
the ARCHITECT c4000 Clinical Chemistry, Abbott Core
Laboratory,[10] LC–MS was performed rarely. More information
about the analytical methods and most common samples used can
be found as online supplement, http://links.lww.com/MD/C98.
The identiﬁcation of cocaine metabolites using MS was
categorized as positive identiﬁcation of cocaine. Furthermore,
for cases of self-reported heroin use, we categorized the detection
of either 6-monoacetylmorphine (6-MAM) or morphine/opiates
as a positive analytical result for heroin because heroin is rapidly
deacetylated into 6-MAM (speciﬁc marker) and then further
metabolized into morphine.3. Results
During the 24-month data collection period, 10,956 cases that
presented with acute recreational drug toxicity were reported to
the Euro-DEN Plus project from the participating centers, with
analytical conﬁrmation available in 1674 cases (15.3%). Among
these cases, 793 (47.4%) were excluded because in those centers
Figure 1. Substances (count of cases) self-reported and/or analytically detected in cases with at least 1 self-reported substance used (n=768).
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results. Of the remaining 881 cases, 50 were excluded because
they only mentioned that an analytical test was performed but the
results were not recorded. The remaining 831 cases were included
in the present analysis—this represents 7.6% of all presentations
and 49.6% of those in whom analytical testing was performed.
Among these 831 cases, at least 1 substance was self-reported
in 768 cases. The substances that were self-reported compared
with those that were identiﬁed analytically are shown in Fig. 1.
The highest agreement between the self-reported substance use
and the toxicological results was found for heroin (86.1%) and
cocaine (74.1%), whereas inhalants, poppers, and magic mush-
rooms were self-reported but not analytically detected. NPS,
excluding SCRAs, that were self-reported and/or analytically
detected are shown in Table 1. In 1 case of self-reported use of
synthetic cannabinoids, the SCRAs 5F-PB-22 and 5F-AKB48
were analytically conﬁrmed using LC–MS/MS.
In 63 cases, no informationwas available from the patient (e.g.,
because of patient unconsciousness or uncooperativeness), or the3agent that was used was unknown to the patient. The substances
that were analytically detected in those cases are shown in Fig. 2.
In 213 of the 831 cases (25.6%), both IA andMS (LC–MS/MS
or GC–MS) test results were available. Comparisons of the IA
and MS results for the most commonly self-reported substances
are shown in Table 2. There was relatively high agreement
(overall percent agreement=positive IA and positive MS plus
negative IA and negative MS/total) between the IA and the MS
ﬁndings for methadone (100%), cocaine (95.5%), and heroin
(91.7%), followed by opioids excluding methadone and heroin
(85.7%), cannabis (84.4%), and benzodiazepines (84.2%), while
the lowest agreement was seen for amphetamines (81.8%). See
Table 2 for positive and negative percent agreement values for
the IA compared with the MS.
Table 3 shows comparisons of the analytical results of both IAs
and additional MS techniques in cases in which amphetamines
were detected, including cases in which no use of these substances
was self-reported (in contrast to Table 2 where only self-reported
substances were considered). Using MS, identiﬁcation of the
Table 1
Self-reported and/or analytically detected NPS (excluding SCRAs).
NPS
Self-reported
(count of cases)
Analytically detected
(count of cases)
Self-reported and analytically
detected (count of cases) Comment
2,5-Dimethoxy-4-bromophenethylamine (2C-B) 2
25B-NBOMe[11] 3
2,5-Dimethoxy-4-chloroamphetamine (DOC) 1 Same case with “Teenage mutant ninja turtle” and 2C-C
“Teenage mutant ninja turtle” 1
2,5-Dimethoxy-4-chlorphenethylamine (2C-C) 1
Paramethoxymethamphetamine (PMMA) 2
Bromo-DragonFLY 1
3-Methylmethcathinone (3-MMC) 1
4-Methylethcathinone (4-MEC) 1
3,4-Methylenedioxypyrovalerone (MDPV) 1
a-PVP 2
Mephedrone 8 3
Methedrone 1
Pentylone[12] 1
Dimethyltryptamine (DMT)[13] 1
“Devil bandit” 1 Toxicological analysis negative
“Charge white” 1 MDMA and ﬂuorophenmetrazine detected
“Blue ghost” 1 Benzodiazepines and methamphetamine detected
a-PVP = a-pyrrolidinopentiophenone, MDMA = 3,4-methylenedioxymethamphetamine, NBOMe= N-2-methoxybenzyl-phenethlylamine; NPS = new psychoactive substances, SCRAs = synthetic cannabinoid
receptor agonists.
Liakoni et al. Medicine (2018) 97:5 Medicineexact substance(s) was possible in 51 of the 54 cases with a
positive IA for amphetamines. Furthermore, amphetamine-type
substances were detected by using MS in 21 cases with a negative
IA, including the NPS pentylone and a-pyrrolidinopentiophe-
none.Figure 2. Substances (count of cases) analytically detected in cases with self-
reported use of an unknown substance or with no information available (n=63).
SSRI=selective serotonin reuptake inhibitor, TCA= tricyclic antidepressants.
44. Discussion
Toxicological analyses were performed only in a minority of the
cases included in the Euro-DEN Plus project, which probably
reﬂects normal practice in most European hospitals. The main
ﬁnding of the present study was an agreement between self-
reports of heroin and cocaine use and the analytical results in
more than two-thirds of the cases. Laughing gas, poppers, magic
mushrooms, g-hydroxybutyrate (GHB), the GHB precursor
g-butyrolactone, NPS, lysergic acid diethylamide (LSD), and
methylphenidate were mainly self-reported but not analytically
detected. Mescaline, phencyclidine (PCP), cathine, and phenyl-
propanolamine were only analytically detected but not self-
reported. In cases in which the substance was unknown by self-
report, the most commonly analytically detected substances were
cocaine, benzodiazepines, and amphetamine-type substances.
Comparisons of the IA and MS results revealed high agreement
for methadone and cocaine but lower agreement for amphet-
amines. Especially for the detection of amphetamine-type
substances the MS detected amphetamines in cases in which
the IA results were negative, and was able to identify the precise
agents, including NPS, in cases of positive IA results. The
probability to detect the self-reported substance was higher with
the IA than MS for the detection of cannabis.
Knowledge of the pharmacological/toxicological properties of
the substances is important for the interpretation of analytical
results. For example, GHB was self-reported and analytically
detected in only 4.5% of the cases, which is likely attributable to
the very short plasma elimination half-life (20–50min) that
results in a small window of detection (4–5h in blood and12
h in urine).[14] In GHB cases, self- or proxy-reported use is the
most important information for diagnosis (95.5% of the cases in
our study). All NPS in the present study were detected only by
additional analytical methods. If NPS use is not self-reported and
if no MS method is used, then NPS use will remain undetected.
Several recent studies on similar patient populations involving
data from poison information centers have also demonstrated the
importance of additional analytical methods in cases of NPS use,
as self-reports have limitations, for example, people do not
[15]
Table 2
Comparison of the analytical results (both IA and MS [LC–MS/MS or GC–MS]) in cases of self-reported use.
MS
Positive Negative Total
Cocaine (n=66)
IA Positive 54 0 54
Negative 3 9 12
Total 57 9 66
Positive, negative, and total percent agreement between IA and MS 94.7% 100% 95.5%
Detected with IA 81.8%
Detected with MS 86.4%
Amphetamine, methamphetamine, or MDMA (n=55)
IA Positive 34 2 36
Negative 8 11 19
Total 42 13 55
Positive, negative, and total percent agreement between IA and MS 81.0% 84.6% 81.8%
Detected with IA 65.5%
Detected with MS 76.4%
Cannabis (n=32)
IA Positive 19 5 24
Negative 0 8 8
Total 19 13 32
Positive, negative, and total percent agreement between IA and MS 100% 61.5% 84.4%
Detected with IA 75%
Detected with MS 59.4%
Heroin (n=24)
IA Positive 21 2 23
Negative 0 1 1
Total 21 3 24
Positive, negative, and total percent agreement between IA and MS 100% 33.3% 91.7%
Detected with IA 95.8%
Detected with MS 87.5%
Benzodiazepines (n=19)
IA Positive 13 2 15
Negative 1 3 4
Total 14 5 19
Positive, negative, and total percent agreement between IA and MS 92.9% 60.0% 84.2%
Detected with IA 78.9%
Detected with MS 73.7%
Methadone (n=9)
IA Positive 8 0 8
Negative 0 1 1
Total 8 1 9
Positive, negative, and total percent agreement between IA and MS 100% 100% 100%
Detected with IA 88.9%
Detected with MS 88.9%
Opioids, excluding heroin and methadone but including tramadol (n=7)
IA Positive 4 1 5
Negative 0 2 2
Total 4 3 7
Positive, negative, and total percent agreement between IA and MS 100% 66.7% 85.7%
Detected with IA 71.4%
Detected with MS 57.1%
GC = gas chromatography, IA = immunoassay, LC = liquid chromatography, MDMA = 3,4-methylenedioxymethamphetamine, MS = mass spectrometry.
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NPS names are often used incorrectly.[16] However, in some
cases, even additional methods cannot detect all NPS (e.g., the
LC–MS/MS method used in Basel was not designed to detect
SCRAs). Furthermore, in cases in which IAs were used to test
for a group of substances (e.g., opiates), certain limitations
should be considered. For example, some synthetic opioids (e.g.,
tramadol) cannot be detected by IA tests for opiates, and Z-drugs
(e.g., zolpidem, zopiclone) cannot be detected by IA tests for
benzodiazepines.[3]5When interpreting analytical results, the possibility that some
substances may be detected but not have clinical relevance should
also be considered. Substances that are taken as comedications
(e.g., antidepressants, methadone) or administered by para-
medics (e.g., benzodiazepines) might be overrepresented in the
analytical results. The same applies for substances with a long
elimination half-life and substances that can be detected in
samples beyond acute intoxication (e.g., cocaine metabolites can
be found 24–48h after use, cannabis is detectable in urine for
days after a single high dose or weeks after heavier chronic
[17]
Table 3
Comparison of IA and MS (LC–MS/MS or GC–MS) results in cases
with analytical detection of amphetamine-type substances.
LC–MS/MS or GC–MS
IA positive for
“amphetamines”
(n=54)
Lone MDMA 26
Lone amphetamine 6
Lone methamphetamine 1
Amphetamine and MDMA 7
Amphetamine and methamphetamine 4
Methamphetamine and mephedrone 2
MDMA and 2C-C 1
Amphetamine and methamphetamine and MDMA 1
Amphetamine and methamphetamine
and mephedrone
1
Amphetamine and MDMA and mephedrone 1
Methamphetamine and MDMA and mephedrone 1
Negative 3
IA negative for
“amphetamines”
(n=21)
Lone amphetamine 10
Lone MDMA 4
Lone methamphetamine 1
Lone pentylone 1
Lone a-PVP 1
Amphetamine and MDMA 3
Amphetamine and methamphetamine 1
a-PVP = a-pyrrolidinopentiophenone, GC = gas chromatography, IA = immunoassay, LC = liquid
chromatography, MDMA = 3,4-methylenedioxymethamphetamine, MS = mass spectrometry.
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to enhance the action of the main substance (e.g., caffeine) can
also be analytically detected without being self-reported or
clinically relevant. Cross-reactivity (i.e., 1 limitation of IAs) can
also lead to false-positives. Some examples of such cross-
reactivity for some IAs include potential positive results for PCP
or cannabis in the presence of lamotrigine, methamphetamine in
the presence of ranitidine, and PCP in the presence of
venlafaxine.[18] Cross-reactivity is a possible explanation for
the 3 cases in the present study that tested positive for
amphetamines with the IAs but negative with the additional
technique.
Basedon thepresent results, additional analyticalmethods appear
to be superior to IAs with regard to the detection of amphetamines.
However, for other substances, IAs appear to deliver accurate
results, with nearly 100% agreement with the MS for substances
such as methadone and cocaine. Possible explanations for the
positive IA results in some cases and negative MS results may be
associated with cross-reactivity or, in the case of cannabis,
limitations of the additional technique that is used (e.g., cannabis
can sometimes stick to the tubes, leading to false-negatives).
The present study has limitations. First, the study was
retrospective and included multiple centers and the toxicological
tests were not performed using the same methods in all of the
centers. Reporting and analytical biases cannot be excluded in
some cases as we used self-reports as references, which have a
varying degree of accuracy, and substances that were not
reported and could not be detected with the method(s) used
would go undetected. Furthermore, some of the substances
detected could be false positives or part of the patient’s
medication. We also did not derive sensitivity values from testing
against gold standards of controlled drug administration but
rather tried to reﬂect the likelihood of detecting a substance that6was reportedly used. For the calculation of sensitivity values,
conﬁrmatory analytical results obtained by LC–MS/MS methods
or similar should be considered the gold standard, and not IA or
self-reports. In order to overcome most of those limitations a
prospective study design using a high-quality test as the gold
standard (e.g., LC–MS/MS) would be needed.5. Conclusion
In conclusion, the present study found high agreement between
self-reported and analytically detected cocaine and heroin use.
Inhalants, poppers, magic mushrooms, GHB, LSD, NPS, and
methylphenidate were mainly self-reported but not analytically
detected. The IAs accurately detected methadone, cocaine, and
heroin. The MS methods presented advantages in detecting NPS
and differentiating amphetamine-type substances. Although
toxicological screening tests are not routinely used in most
hospitals across Europe, our ﬁndings suggest that they can be
helpful, mostly in cases of use of unknown agents and unclear
clinical presentations, provided that the results are interpreted
correctly.
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